OSLO, Norway, May 3, 2023 /PRNewswire/ — Lytix Biopharma – Lytix Biopharma AS (“Lytix”) (Euronext Growth Oslo: LYTIX), a Norwegian immuno-oncology company – is pleased to announce that Dr Øystein Rekdal, CEO in Lytix Biopharma, today will give an oral presentation at the `Frontiers in…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.